Mirxes Holding Company Limited (HKG:2629)

Market Cap	11.61B
Revenue (ttm)	166.32M
Net Income (ttm)	-598.38M
Shares Out	273.30M
EPS (ttm)	-4.38
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	871,300
Average Volume	378,595
Open	43.10
Previous Close	42.48
Day's Range	41.06 - 44.60
52-Week Range	27.05 - 77.30
Beta	n/a
RSI	40.61
Earnings Date	May 15, 2026

About Mirxes Holding Company

Mirxes Holding Company Limited, a micro ribonucleic acid technology company, provides diagnostic solutions for the screening of cancer, cardiovascular, metabolic, and infectious diseases accessible across Singapore and China. The company offers GASTROClear, a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening; LUNGClear, a lung cancer screening product candidate; and Fortitude COVID-19 RT-qPCR test kits. It also researches, develops, and manufactures biotechnology, life, and medical science related ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 347
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2629

Financial Performance

In 2024, Mirxes Holding Company's revenue was $20.28 million, a decrease of -16.14% compared to the previous year's $24.19 million. Losses were -$92.33 million, 33.4% more than in 2023.

Financial numbers in USD